Completed

A Study to Evaluate Nutropin AQ for the Treatment of Growth Restriction in Children With Cystic Fibrosis

0 criteria met from your profileSee at a glance how your profile meets each eligibility criteria.
What is being tested

Nutropin AQ [somatropin (DNA origin) injection]

Drug
Who is being recruted

Cystic Fibrosis

From 5 to 13 Years
+19 Eligibility Criteria
How is the trial designed

Treatment Study

Phase 2
Interventional
Study Start: September 2003

Summary

Principal SponsorGenentech, Inc.
Last updated: June 9, 2008
Sourced from a government-validated database.Claim as a partner
Study start date: September 1, 2003Actual date on which the first participant was enrolled.

This is a Phase II, multicenter, randomized, controlled, open-label trial of the safety and efficacy of Nutropin AQ administered subcutaneously (SC) daily in prepubertal children with CF and growth restriction.

Official TitleA Phase II, Multicenter, Randomized, Controlled, Open-Label Study of the Safety and Efficacy of Nutropin AQ [Somatropin (DNA Origin) Injection] for the Treatment of Growth Restriction in Children With Cystic Fibrosis 
Principal SponsorGenentech, Inc.
Last updated: June 9, 2008
Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.
Design Details
68 patients to be enrolledTotal number of participants that the clinical trial aims to recruit.
Treatment Study
These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.
Conditions
Criteria
Any sexBiological sex of participants that are eligible to enroll.
From 5 to 13 YearsRange of ages for which participants are eligible to join.
Healthy volunteers not allowedIf individuals who are healthy and do not have the condition being studied can participate.
Conditions
Pathology
Cystic Fibrosis
Criteria
9 inclusion criteria required to participate
Ability of parent or legal guardian to provide written informed consent and, if applicable, pediatric assent and compliance with study assessments for the full duration of the study

Diagnosis of CF by sweat or genetic testing

Between the ages of 5 and 12 years for girls and 5 and 13 years for boys

Ability to perform pulmonary function tests in a reproducible manner, per American Thoracic Society guidelines for spirometry


10 exclusion criteria prevent from participating
Prior or current rhGH use

History of short stature due to GHD

History within the 12 months prior to screening of glucose intolerance (impaired glucose tolerance) or CF-related diabetes (CFRD) as defined by at least one of the following: fasting serum glucose of >= 126 mg/dL on two or more occasions; fasting serum glucose of \>= 126 mg/dL plus any casual (previously called random) glucose level \>= 200 mg/dL; casual (previously called random) glucose of \>= 200 mg/dL on two or more occasions; fasting serum glucose of <= 126 mg/dL but 2-hour post oral glucose load of 140-199 mg/dL (impaired glucose tolerance) on two or more occasions; if a subject meets the criteria for impaired glucose tolerance or CFRD in the screening glucose tolerance test, even if there is no history of impaired glucose tolerance, the subject will not be eligible for the study

Infection with Burkholderia cepacia


Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.
Study Objectives
Study Objectives
Primary Objectives

Secondary Objectives


Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.
This study has no location dataSave this study to your profile to know when the location data is available. 

CompletedNo study centers